The best therapeutic options for serious infections due to daptomycin nonsusceptible Enterococcus faecium (DNSE) remain unclear. We report the use of daptomycin for the treatment of DNSE bacteremia. To our knowledge, it is the fırst case of DNSE infection which successfully treated with daptomycin monotherapy in the literature. 
INTRODUCTION
Bacteremia caused by vancomycin-resistant enterococci (VRE) has been associated with higher morbidity and mortality than caused by vancomycin susceptible enterococci. 1 The optimal approach for treatment of enterococcal infection due to vancomycin-resistant E. faecium is uncertain. 2 Although daptomycin has not been approved by the FDA for E. faecium, some favor the use of daptomycin for treatment of E. faecium infections that are resistant in vitro to approved antibiotics. 2 Minimum dosing for bloodstream infections is 6 mg/kg intravenously once daily; in the setting of bloodstream infections some favor doses of 8 mg/kg intravenously once daily or higher. Higher dosing (8 to 12 mg/kg every 24 hours) may be more efficacious for life threatening infections due to E. faecalis or E. faecium. 3 Daptomycin has concentration-dependent killing and in vivo data have shown that higher doses. 4 The knowledge about the emergence of daptomycin nonsusceptible Enterococcus strains and the treatment of the associated infections is limited. 5 Daptomycin nonsusceptibility among staphylococci has been reported in Turkey. 6, 7 We describe the first case which reported from Turkey of a patient with loss of daptomycin susceptibility among enterococci after daptomycin treatment.
CASE REPORT
In September 2010 a 36-year-old woman admitted to our neurosurgical intensive care unit (ICU) because she had a diffuse axonal injury due to a traffic accident. A subclavian nontunneled catheter was inserted and she was treated medically without any surgical intervention. On the ninth day of the admission she was found to have fever of 39°C and erythema at the catheter exit site. She was considered to have catheter related infection. Two blood 
DISCUSSION
Vancomycin resistant enterococci (VRE) are important cause of nosocomial bloodstream infection (BSI). 8, 9 There are limited treatment options currently available for the treatment of VRE infections. 8 Daptomycin is a cyclic lipopeptide antibiotic with rapid bactericidal activity against drug-resistant bacteria including methicillin-resistant Staphylococcus aureus and VRE. 10 Neither Clinical Laboratory Standards Institute (CLSI) nor the European Committee on Antimicrobial Susceptibility Testing (EUCAST) committees have defined resistance breakpoints for enterococci to daptomycin. EUCAST defined insufficient evidence to set a breakpoint for enterococci. 11 According to CLSI Enterococcus isolates with minimum inhibitory concentrations (MICs) ≤4 µg, determined by broth dilution are considered susceptible. 12 Moreover, enterococci with daptomycin MICs >4 µg/ml are considered as non-susceptible (DNSE).
11 Strains with MICs above the established breakpoint are not often encountered. From 2003 through 2010 there are 23 studies reporting 150 DNSE. Of these 150 isolates, 140 (93.3%) were VRE, nine were vancomycin susceptible enterococci (VSE) and in one (0.7%) case, vancomycin susceptibility was not reported. 5 Treatment of DNSE isolates was reported in nine cases. All cases had underlying diseases impairing the immune functions of the patients, were treated with alternative agents other than daptomycin and four of them were cured. 5, 12 The optimal management of serious DNSE infection is unknown.5 Currently there is no available literature comparing the efficacy of various doses of daptomycin in relation to MIC values. 13 Daptomycin displays concentration-dependent activity that is best characterized by pharmacodynamic indexes AUC/MIC or Cmax/MIC. The pharmacodynamics of daptomycin for E. faecium was characterized in the neutropenic mouse model. The AUC/MIC ratios required for bacteriostatic effect ranged from 0.94 to 1.67 for E. faecium. The free daptomycin concentrations needed were an average of one to two times the MIC over 24 hours to produce a bacteriostatic effect and two to four times the MIC over 24 hours to produce greater than 99% killing. 4 For the human situation, it can be calculated that a mean AUC of approximately 858 mg h/l (as Our case didn't have any co-morbidities causing immune impairment. This may also have contributed for the cure of our patient unlike the other reported cases of treatment failure. In our case Enterococcus faecium was resistant to all other antibiotic agents and we treated the patient with daptomycin as we didn't have any other choice. Although there are no defined MIC breakpoints for a resistant category for Enterococcus according to CLSI or EU-CAST, to our knowledge it is the fırst case of DNSE infection successfully treated with daptomycin in the literature. As a result prospective studies are needed to fully understand the use of daptomycin in the treatment of DNSE bacteremia.
